# Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report No Results Phase 3 results in SAM-002

> No Results leads at 71%, runner-up 16% across 5 winner-take-all outcomes — refreshed 42 min ago.

URL: https://simplefunctions.dev/odds/samson
Updated: 2026-06-26T13:20:51.553Z
Category: general · Topic: oil
Status: active
Closes: 2026-07-01

## Headline

- Leader: No Results at 71%
- Runner-up: Success at 16%
- Outcomes: 5 (winner-take-all)
- Venue: Kalshi (5 contracts)
- 24h volume: $560

## Bound contracts (5)

| Outcome | Price | 24h | Volume | Venue | Slug |
|---|---|---|---|---|---|
| No Results | 71¢ | ±0 | $560 | kalshi | /markets/will-samson-clinical-operationss-male-androgenetic-kalshi-kxsamson-26-sam-002-nr |
| Success | 16¢ | −1pp | $0 | kalshi | /markets/will-samson-clinical-operationss-male-androgenetic-kalshi-kxsamson-26-sam-002-suc |
| Failure | 5¢ | −1pp | $0 | kalshi | /markets/will-samson-clinical-operationss-male-androgenetic-kalshi-kxsamson-26-sam-002-fail |
| Mixed | 3¢ | +3pp | $0 | kalshi | /markets/will-samson-clinical-operationss-male-androgenetic-kalshi-kxsamson-26-sam-002-mix |
| Ambiguous | 3¢ | — | $0 | kalshi | /markets/will-samson-clinical-operationss-male-androgenetic-kalshi-kxsamson-26-sam-002-amb |

## 30-day trajectory

| Day | No Results | Success | Failure |
|---|---|---|---|
| 2026-06-10 | 66 | 17 | 5 |
| 2026-06-11 | 65 | — | — |
| 2026-06-12 | — | — | 7 |
| 2026-06-18 | 67 | 17 | 6 |
| 2026-06-19 | 66 | 17 | 2 |
| 2026-06-20 | 66 | 18 | 4 |
| 2026-06-25 | — | 20 | 4 |

_13 days of price history captured. Each row is the daily mean of intraday 5-min captures._

## What moved the line

- 2026-06-19 · Failure −4pp 6→2¢ · kalshi
- 2026-06-24 · Success +3pp 18→21¢ · kalshi
- 2026-06-26 · Mixed +3pp 5→8¢ · kalshi

## Analysis

This market reflects a 65% probability that Samson Clinical Operations' sublingual minoxidil treatment for male hair loss will report inconclusive or unsuccessful Phase 3 results in the SAM-002 trial. The high probability of negative or ambiguous outcomes suggests market participants assign meaningful risk to the drug failing to demonstrate efficacy sufficient for regulatory approval. Current market pricing is driven by baseline skepticism about sublingual minoxidil as a novel delivery mechanism for a known compound, though limited recent clinical data appears publicly available. The resolution hinges on when Samson reports Phase 3 trial results, which would definitively establish whether the formulation met its primary efficacy endpoints. This matters because positive results would represent a new treatment option for androgenetic alopecia, while negative results would redirect the company's development priorities.

### Key factors

- Sublingual minoxidil is a reformulation of an existing compound; market may be pricing in difficulty demonstrating meaningful advantage over established topical delivery
- Phase 3 trial design specifics (primary endpoints, patient population, comparator choice) would significantly influence outcome probability if disclosed
- Absence of publicly available interim data or recent company updates may reflect either deliberate information control or lack of compelling preliminary signals
- Timeline to results announcement remains undefined; extended timelines without updates typically correlate with lower success probability in biotech markets
- Competitor landscape and regulatory precedent for other novel hair-loss formulations could shift probability if new approvals or failures occur

## Methodology

Headline is the **leader's price**, not an arithmetic mean — averaging disjoint winner-take-all outcomes is meaningless. Per-outcome prices come from the venue's last-traded mid; cross-venue values are simple means across contracts on each venue.

## How to use this data

- HTML: https://simplefunctions.dev/odds/samson
- JSON: https://simplefunctions.dev/api/public/odds?slug=samson
- Topic hub: https://simplefunctions.dev/predictions/oil

## License

CC-BY-4.0. Attribute "SimpleFunctions" with a link to https://simplefunctions.dev. See https://simplefunctions.dev/legal for terms.